Jump to content

User:Beaker 3.1/sandbox

From Wikipedia, the free encyclopedia

Expressivity (Genetics)

[edit]

Introduction

[edit]

In genetics, expressivity quantifies the variation in expression of a non-binary phenotype across individuals carrying a particular genotype. It refers to the proportion of individuals that are carriers of a given genotype for a trait of interest, showing it to a specifiable extent. Expressivity therefore characterizes non-binary qualitatively or quantitatively to the extent of phenotypic variation within a particular genotype. A qualitative example, in the hypothetical example of a "blue" gene, the gene might have an expressivity of 25% for individuals that express the "blue" gene and appear light blue, while for individuals who express the blue and appear dark blue, the expressivity might be 75%.

Variable Expressivity

[edit]

Variable expressivity refers to the degree in which a genotype is phenotypically expressed. For example, multiple people with the same disease can have the same genotype but one may express more severe symptoms, while another carrier may appear normal. This variation in expression can be affected by modifier genes, epigenetic factors or the environment.[1] Modifier genes can alter the expression of other genes in either an additive or multiplicative way.[2] Meaning the phenotype that is observed can be a result of two different alleles being summed or multiplied. However, a reduction in expression may also occur in which the primary locus, where the phenotype is expressed, is affected.[3] Epigenetic factors, such as cis-regulatory elements, can also cause variability in expression by inducing variation in transcript abundance.[4]

Variability differs from penetrance, which refers to the proportion of genotypes that actually express or show the expected phenotype.[5] For example, for a population with known genotypes, where all individuals have the same allele pattern for a given trait of interest, we find that only 75% of the population express the expected phenotype of their allele combination. In this example, penetrance would be defined as 75%. This differs from expressivity because while penetrance describes variability in phenotype expression at the broader population level, expressivity is a measure of phenotype variability at the individual level.

Expressivity Examples

[edit]
Figure 1: Affected individuals usually have fingers that are longer than those that do not have the syndrome. The extremity of difference in finger length is a result of variable expressivity.

Three common syndromes that involved phenotypic variability due to expressivity include: Marfan syndrome, Van der Woude Syndrome, and Neurofibromatosis.

Figure 2: Example of Cleft lip seen as a result of the Van der Woude syndrome.

The characteristics of Marfan syndrome widely vary among individuals. The syndrome affects connective tissue in the body and has a spectrum of symptoms ranging from mild bone and joint involvement to severe neonatal forms and cardiovascular disease.[6] This diversity in symptoms is a result of variable expressivity of the FBN1 gene found on chromosome 15 (see figure 1).[7] The gene product is involved in the proper assembly of microfibrils.[7]

Van der Woude syndrome is a condition that affects the development of the face, specifically a cleft lip (see figure 2), cleft palate or both .[8] Carriers of the mutation can also have pits near the centre of the lower lip which may appear to be wet due to the presence of salivary glands.[8] The resulting phenotypes expressed varies significantly among individuals. This variation can range so broadly that a study published by the Department of Orthodontics at the University of Athens showed that some individuals were unaware that they possessed the genotype for this condition until they were tested.[9]

Neurofibromatosis (NF1),also known as Von Recklinghausen disease, is a genetic disorder that is caused by a mutation in the neurofibromin gene NF1 on chromosome 17.[10] A loss of function mutation in the tumor suppressor gene can cause tumors on the nerves called neurofibromas.[11] These appear as small bumps under the skin. It is stipulated that the phenotypic variation is a result of unlinked genetic modifiers.[12]



See also

[edit]

References

[edit]
  1. ^ Marian, A. J.; Roberts, R. (2001-04-01). "The Molecular Genetic Basis for Hypertrophic Cardiomyopathy". Journal of Molecular and Cellular Cardiology. 33 (4): 655–670. doi:10.1006/jmcc.2001.1340. ISSN 0022-2828.
  2. ^ Marian, A. J.; Roberts, R. (2001-04-01). "The Molecular Genetic Basis for Hypertrophic Cardiomyopathy". Journal of Molecular and Cellular Cardiology. 33 (4): 655–670. doi:10.1006/jmcc.2001.1340. ISSN 0022-2828.
  3. ^ Slavotinek, Anne; Biesecker, Leslie G. (2003-04-02). "Genetic modifiers in human development and malformation syndromes, including chaperone proteins". Human Molecular Genetics. 12 (suppl_1): R45–R50. doi:10.1093/hmg/ddg099. ISSN 0964-6906.
  4. ^ Peaston, Anne E.; Whitelaw, Emma (2006). "Epigenetics and phenotypic variation in mammals". Mammalian Genome. 17 (5): 365–374. doi:10.1007/s00335-005-0180-2. ISSN 0938-8990. PMC 3906716. PMID 16688527.
  5. ^ "Phenotype Variability: Penetrance and Expressivity | Learn Science at Scitable". www.nature.com. Retrieved 2019-11-13.
  6. ^ Reference, Genetics Home. "Marfan syndrome". Genetics Home Reference. Retrieved 2019-10-09.
  7. ^ a b Reference, Genetics Home. "FBN1 gene". Genetics Home Reference. Retrieved 2019-10-09.
  8. ^ a b Reference, Genetics Home. "Van der Woude syndrome". Genetics Home Reference. Retrieved 2019-10-09.
  9. ^ Rizos, Maria; Spyropoulos, Meropi N. (2004-02-01). "Van der Woude syndrome: a review. Cardinal signs, epidemiology, associated features, differential diagnosis, expressivity, genetic counselling and treatment". European Journal of Orthodontics. 26 (1): 17–24. doi:10.1093/ejo/26.1.17. ISSN 0141-5387.
  10. ^ "Neurofibromatosis". medlineplus.gov. Retrieved 2019-10-09.
  11. ^ Sabbagh, Audrey; Pasmant, Eric; Laurendeau, Ingrid; Parfait, Béatrice; Barbarot, Sébastien; Guillot, Bernard; Combemale, Patrick; Ferkal, Salah; Vidaud, Michel; Aubourg, Patrick; Vidaud, Dominique (2009-08-01). "Unravelling the genetic basis of variable clinical expression in neurofibromatosis 1". Human Molecular Genetics. 18 (15): 2768–2778. doi:10.1093/hmg/ddp212. ISSN 0964-6906. PMC 2722187. PMID 19417008.
  12. ^ Sabbagh, Audrey; Pasmant, Eric; Laurendeau, Ingrid; Parfait, Béatrice; Barbarot, Sébastien; Guillot, Bernard; Combemale, Patrick; Ferkal, Salah; Vidaud, Michel; Aubourg, Patrick; Vidaud, Dominique (2009-08-01). "Unravelling the genetic basis of variable clinical expression in neurofibromatosis 1". Human Molecular Genetics. 18 (15): 2768–2778. doi:10.1093/hmg/ddp212. ISSN 0964-6906. PMC 2722187. PMID 19417008.